Atrys participates in a European project
February 27, 2014
The project, with a budget of € 22.5 million and a duration of 5 years, is funded equally by the Seventh Framework Program (FP7) and the European Federation of Pharmaceutical Industry Associations (EFPIA).
On February 20, the European project for innovative medicines PRECISESADS was launched in Brussels, with the participation of 23 research centers of the academic world and 5 industrial partners, among which is Althia. The study will include more than 2,000 European patients with autoimmune diseases and six hundred healthy individuals as a control. The novel multidisciplinary approach aims to study at the molecular level some of the most common autoimmune diseases: lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjogren's syndrome and PAPS, diseases that individually can be considered as not very prevalent, but which together affect a 1% of the population. Knowledge of the molecular signature of these diseases will allow the development of more powerful diagnostic and prognostic tools, as well as the design of more effective therapies within the concept of individualized medicine.